COVID-19: a viewpoint from hepatic perspective.

Abstract

Coronaviruses as such are known since last century. The name is derived from their shape which hascrown (corona) like radiating spikes. The recent one however is a different one from the Coronavirus involved inSARS (2002-2004) and MERS (2012) in being highly infectious. Initially COVID 19 had a high case fatality rate which has now decreased to a significant extent. Many cases of COVID 19 are asymptomatic with a significant number of positive cases developing a triad of fever, breathlessness and GI symptoms. Recent travel increases the probability of infection. The pathogenesis involves ACE 2 receptors. So, it has been found that there are more cases and mortality among hypertensive individuals. Even higher among the people who use ACE inhibitor in comparison to those who use other anti-hypertensive drugs. Treatment is usually symptomatic. Antiviral drugs and vaccines against COVID-19 are being used. Deranged liver enzymes are common in COVID-19, however, serious liver injury is not much documented. Liver injury is either due to disease itself or due to antiviral drugs. Extra care like strict social distancing, avoiding unnecessary contact is needed for those with autoimmune hepatitis, liver cancer and those who are in immunosuppression because of a scheduled oralready liver transplant. Further research is definitely needed in this field. The upcoming researches should also focus on liver injuries associated with disease course andderangements arising as side effects of treatment of COVID-19.